Liposome Di-adjuvant B is a specialized cholesterol- and phospholipid-based bilayer liposome formulation designed for advanced vaccine and immunotherapy research. It contains QS-21 and 3D-MPLA, each at 100 µg/ml, making it a dual-adjuvant system suitable for applications where strong and controlled immune stimulation is required. This formulation is positioned for research-grade and GMP-grade use, supporting development workflows in areas such as herpes zoster vaccine research, neurodegenerative disease vaccine research, and other next-generation immunological studies. The bilayer liposome architecture is intended to improve the presentation and delivery of adjuvant components, helping researchers work with a structured lipid-based platform rather than a simple mixed solution. Cholesterol and phospholipid composition is a key advantage for applications that require membrane-mimicking stability and reproducible formulation behavior. Because of its dual-adjuvant configuration, Liposome Di-adjuvant B is especially relevant for B2B buyers involved in vaccine R&D, pharmaceutical formulation, biotechnology development, and preclinical research programs that require consistent, high-quality adjuvant materials. For laboratories and manufacturers seeking a research-focused liposomal adjuvant solution, this product offers a distinct combination of QS-21 and 3D-MPLA in a ready-to-use bilayer liposome format. Its defined concentration and quality levels make it suitable for controlled studies, formulation screening, and product development in modern immunology pipelines.

*Disclaimer: The above description has been AI-generated and has not been audited or verified for accuracy. It is recommended to verify product details independently before making any purchasing decisions.